CompaniesH3 Biomedicine

H3 Biomedicine

defunct
About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (4)
View all

Total Trials

4

As Lead Sponsor

1

As Collaborator

3

Total Enrollment

169

By Phase

PHASE1: 4

By Status

COMPLETED: 2TERMINATED: 1WITHDRAWN: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2015
2016
2017
2018
2019
2020
2021
2022
2023
Today
NCT02834780
NCT04109092
NCT04144140
Hover over trial bars to see details

Recent Trials

NCT04144140Collaborator
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101
PHASE1Terminated
24 participants
Started: Feb 24, 2020 · Completed: Jul 26, 2022
NCT04109092Collaborator
A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102
PHASE1Withdrawn
Started: Feb 13, 2020 · Completed: Sep 29, 2022
NCT03424577Collaborator
A Study to Evaluate the Food-Effect of H3B-6527
PHASE1Completed
17 participants
Started: Dec 27, 2017 · Completed: Jan 27, 2018
NCT02834780Lead Sponsor
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
PHASE1Completed
128 participants
Started: Dec 28, 2016 · Completed: Feb 23, 2022